{
    "clinical_study": {
        "@rank": "4988", 
        "arm_group": [
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper."
            }, 
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper."
            }
        ], 
        "brief_summary": {
            "textblock": "Dyslipidemia contributes greatly to the formation and progression of atherosclerosis (AS),\n      which plays a dominant role in leading to CHD.\n\n      Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus).\n      It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol,amino\n      acids, flavonoids, alkaloid, trace element, and so forth. Xuezhikang has been recommended in\n      a guideline for China adult dyslipidemia prevention.\n\n      This study aims to evaluate the benefit and side effect of Xuezhikang, a potential\n      alternative drug of statins, for patients with dyslipidemia, and thus provide further\n      evidence for clinical application."
        }, 
        "brief_title": "A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia", 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: 18 years to 75 years\n\n          2. Patients with Dyslipidemia should be diagnosed according to standard western medicine\n             diagnosis criteria\n\n          3. TCM syndrome of patients with dyslipidemia should be diagnosed according to standard\n             TCM syndrome diagnosis criteria\n\n          4. Patients who have taken lipid lowering drugs should stop taking for at least two\n             weeks before taking part in this study\n\n          5. Patients agree to participate in this study and signed the informed consent form\n\n        Exclusion Criteria:\n\n          1. Pregnant (positive pregnancy test within 7 days of starting treatment), or lactating\n             women.\n\n          2. Patients with Homozygous Familial Hypercholesterolemia\n\n          3. Patients with known allergy to Chinese medicine or any other drug\n\n          4. Patients with acute myocardial infarction, cerebrovascular accident , severe trauma ,\n             major surgery and cancer in half a year.\n\n          5. AST or ALT level increases at least twice the upper limits of normal in patients\n\n          6. Patients who are taking part in other clinical trials that will influence the results\n             of this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2400", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057302", 
            "org_study_id": "2008ZX09202-007"
        }, 
        "intervention": {
            "arm_group_label": "Group A", 
            "intervention_name": "Xuezhikang capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Xuezhikang Dyslipidemia chinese medicine RCT", 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study", 
        "other_outcome": {
            "measure": "safety outcomes including vital signs and laboratory tests", 
            "safety_issue": "Yes", 
            "time_frame": "to detect the change from baseline to 8th week"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Blood samples were drawn were detected,including TC,TG,LDL-C and HDL-C", 
            "safety_issue": "No", 
            "time_frame": "the detect the change from baseline to the 8th week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057302"
        }, 
        "responsible_party": {
            "investigator_affiliation": "China  Academy of Chinese Medical Sciences", 
            "investigator_full_name": "Xing Liao", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Traditional Chinese medicine syndrome scores (TCM-SS) and single TCM symptom", 
            "safety_issue": "No", 
            "time_frame": "to detect the change at baseline, 2nd week, 4th week, 6th week, and 8th week"
        }, 
        "source": "China  Academy of Chinese Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "China  Academy of Chinese Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}